Literature DB >> 15073463

Managing hypertension in African-American patients.

Elijah Saunders1.   

Abstract

Epidemiologic evidence indicates that African Americans are at greater risk for hypertension compared with other ethnic groups in the United States. The prevalence of hypertension is estimated to be approximately 37% for this group, compared with 20%-25% for non-Hispanic whites. Hypertension seems to follow a more malignant course in African Americans, possibly as a result of the higher prevalence of concomitant cardiovascular risk factors in this population. Compared with white persons with hypertension, these patients are at increased risk for left ventricular hypertrophy, heart failure, and end-stage renal disease. Data suggest that ethnicity may influence the response to certain types of antihypertensive medication. Additional data indicate that more aggressive use of combination therapy may improve clinical outcomes among high-risk hypertensive patients. Based on these findings, recommendations are made for the optimal clinical management of hypertension in African-American patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15073463      PMCID: PMC8109664          DOI: 10.1111/j.1524-6175.2004.03564.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  27 in total

1.  Characteristics of patients with uncontrolled hypertension in the United States.

Authors:  D J Hyman; V N Pavlik
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

2.  Physician Role in Lack of Awareness and Control of Hypertension.

Authors:  David J. Hyman; Valory N. Pavlik; Carlos Vallbona
Journal:  J Clin Hypertens (Greenwich)       Date:  2000-10       Impact factor: 3.738

3.  A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks.

Authors:  E Saunders; M R Weir; B W Kong; J Hollifield; J Gray; V Vertes; J R Sowers; M B Zemel; C Curry; J Schoenberger
Journal:  Arch Intern Med       Date:  1990-08

Review 4.  Pathophysiology of chronic progressive renal disease in the African American patient with hypertension.

Authors:  Lonzetta Neal; Eddie L Greene
Journal:  Am J Med Sci       Date:  2002-02       Impact factor: 2.378

5.  Effect of carvedilol on survival in severe chronic heart failure.

Authors:  M Packer; A J Coats; M B Fowler; H A Katus; H Krum; P Mohacsi; J L Rouleau; M Tendera; A Castaigne; E B Roecker; M K Schultz; D L DeMets
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

6.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.

Authors:  L Y Agodoa; L Appel; G L Bakris; G Beck; J Bourgoignie; J P Briggs; J Charleston; D Cheek; W Cleveland; J G Douglas; M Douglas; D Dowie; M Faulkner; A Gabriel; J Gassman; T Greene; Y Hall; L Hebert; L Hiremath; K Jamerson; C J Johnson; J Kopple; J Kusek; J Lash; J Lea; J B Lewis; M Lipkowitz; S Massry; J Middleton; E R Miller; K Norris; D O'Connor; A Ojo; R A Phillips; V Pogue; M Rahman; O S Randall; S Rostand; G Schulman; W Smith; D Thornley-Brown; C C Tisher; R D Toto; J T Wright; S Xu
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

7.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

8.  Trends in hospitalization rates for heart failure in the United States, 1973-1986. Evidence for increasing population prevalence.

Authors:  J K Ghali; R Cooper; E Ford
Journal:  Arch Intern Med       Date:  1990-04

9.  Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group.

Authors:  M R Weir; J M Gray; R Paster; E Saunders
Journal:  Hypertension       Date:  1995-07       Impact factor: 10.190

Review 10.  The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview.

Authors:  R S Vasan; D Levy
Journal:  Arch Intern Med       Date:  1996-09-09
View more
  6 in total

1.  Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients.

Authors:  Elizabeth O Ofili; Dion H Zappe; Das Purkayastha; Rita Samuel; James R Sowers
Journal:  Am J Ther       Date:  2013-01       Impact factor: 2.688

Review 2.  Executive summary of the African-American Initiative.

Authors:  Clyde W Yancy
Journal:  MedGenMed       Date:  2007-02-08

3.  Relationship Between Risks for Obstructive Sleep Apnea, Resistant Hypertension, and Aldosterone Among African American Adults in the Jackson Heart Study.

Authors:  Patrick Koo; Paul Muntner; Michael E Hall; Annie Gjelsvik; Franklin Dennis McCool; Charles B Eaton
Journal:  Am J Hypertens       Date:  2022-10-03       Impact factor: 3.080

4.  Hypertension control among African Americans: an urgent call for action.

Authors:  Daniel T Lackland
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-06       Impact factor: 3.738

5.  Severity of systemic sclerosis-associated pulmonary arterial hypertension in African Americans.

Authors:  Isabel Blanco; Stephen Mathai; Majid Shafiq; Danielle Boyce; Todd M Kolb; Hala Chami; Laura K Hummers; Traci Housten; Neal Chaisson; Ari L Zaiman; Fredrick M Wigley; Ryan J Tedford; David A Kass; Rachel Damico; Reda E Girgis; Paul M Hassoun
Journal:  Medicine (Baltimore)       Date:  2014-07       Impact factor: 1.889

Review 6.  The disproportionate impact of hypertensive cardiovascular disease in African Americans: getting to the heart of the issue.

Authors:  Kenneth A Jamerson
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-04       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.